#kp33 — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #kp33, aggregated by home.social.
-
#Russia, Rospotrebnadzor warns of rapid #spread of new #COVID strain, https://regnum.ru/news/3917704
The department reported that #XEC is a recombinant of 2 earlier subvariants of #Omicron coronavirus strain — FLiRT — #KS11 & #KP33. Symptoms of new variant are similar to previous ones. Patients complain of fever, sore throat, cough, & loss of smell. Infected people may also experience loss of appetite, body aches, headache, runny nose, and fatigue.
-
#Russia, Rospotrebnadzor warns of rapid #spread of new #COVID strain, https://regnum.ru/news/3917704
The department reported that #XEC is a recombinant of 2 earlier subvariants of #Omicron coronavirus strain — FLiRT — #KS11 & #KP33. Symptoms of new variant are similar to previous ones. Patients complain of fever, sore throat, cough, & loss of smell. Infected people may also experience loss of appetite, body aches, headache, runny nose, and fatigue.
-
#Russia, Rospotrebnadzor warns of rapid #spread of new #COVID strain, https://regnum.ru/news/3917704
The department reported that #XEC is a recombinant of 2 earlier subvariants of #Omicron coronavirus strain — FLiRT — #KS11 & #KP33. Symptoms of new variant are similar to previous ones. Patients complain of fever, sore throat, cough, & loss of smell. Infected people may also experience loss of appetite, body aches, headache, runny nose, and fatigue.
-
#Russia, Rospotrebnadzor warns of rapid #spread of new #COVID strain, https://regnum.ru/news/3917704
The department reported that #XEC is a recombinant of 2 earlier subvariants of #Omicron coronavirus strain — FLiRT — #KS11 & #KP33. Symptoms of new variant are similar to previous ones. Patients complain of fever, sore throat, cough, & loss of smell. Infected people may also experience loss of appetite, body aches, headache, runny nose, and fatigue.
-
#Russia, Rospotrebnadzor warns of rapid #spread of new #COVID strain, https://regnum.ru/news/3917704
The department reported that #XEC is a recombinant of 2 earlier subvariants of #Omicron coronavirus strain — FLiRT — #KS11 & #KP33. Symptoms of new variant are similar to previous ones. Patients complain of fever, sore throat, cough, & loss of smell. Infected people may also experience loss of appetite, body aches, headache, runny nose, and fatigue.
-
#Escape of #SARS-CoV-2 #variants #KP11, #LB1 and #KP33 from approved #mAbs http://biorxiv.org/cgi/content/short/2024.08.20.608835v1?rss=1
#Sipavibart neutralized JN.1.1 but lost antiviral efficacy against KP1.1, LB.1 and KP3.3. Our results highlight the need for a close clinical monitoring of Pemivibart and raise concerns about the clinical efficacy of Sipavibart.
-
#Escape of #SARS-CoV-2 #variants #KP11, #LB1 and #KP33 from approved #mAbs http://biorxiv.org/cgi/content/short/2024.08.20.608835v1?rss=1
#Sipavibart neutralized JN.1.1 but lost antiviral efficacy against KP1.1, LB.1 and KP3.3. Our results highlight the need for a close clinical monitoring of Pemivibart and raise concerns about the clinical efficacy of Sipavibart.
-
#Escape of #SARS-CoV-2 #variants #KP11, #LB1 and #KP33 from approved #mAbs http://biorxiv.org/cgi/content/short/2024.08.20.608835v1?rss=1
#Sipavibart neutralized JN.1.1 but lost antiviral efficacy against KP1.1, LB.1 and KP3.3. Our results highlight the need for a close clinical monitoring of Pemivibart and raise concerns about the clinical efficacy of Sipavibart.
-
#Escape of #SARS-CoV-2 #variants #KP11, #LB1 and #KP33 from approved #mAbs http://biorxiv.org/cgi/content/short/2024.08.20.608835v1?rss=1
#Sipavibart neutralized JN.1.1 but lost antiviral efficacy against KP1.1, LB.1 and KP3.3. Our results highlight the need for a close clinical monitoring of Pemivibart and raise concerns about the clinical efficacy of Sipavibart.
-
#Escape of #SARS-CoV-2 #variants #KP11, #LB1 and #KP33 from approved #mAbs http://biorxiv.org/cgi/content/short/2024.08.20.608835v1?rss=1
#Sipavibart neutralized JN.1.1 but lost antiviral efficacy against KP1.1, LB.1 and KP3.3. Our results highlight the need for a close clinical monitoring of Pemivibart and raise concerns about the clinical efficacy of Sipavibart.